pharmaphorum

JUNE 28, 2022

For Astellas, the alliance takes the spotlight off the current travails with its gene therapy programmes, with an FDA clinical hold imposed on another candidate – for Pompe disease – in the last few days. The post Astellas pumps $90m into Sutro immuno-oncology alliance appeared first on.

Biopharma 91

Biopharma Patients FDA Marketing 91

Pharmaceutical Technology

JULY 13, 2022

The initial agreement was signed in February 2020 for discovering, developing and marketing new immuno-oncology therapies based on Bicycle’s bicyclic peptide technology. The agreement is exclusive of the compounds in the oncology pipeline of Bicycle, including its immuno-oncology candidates.

Marketing 59

Marketing Pharmaceutical 59

Pharmaceutical Technology

DECEMBER 19, 2022

Sanofi has extended the partnership with Innate Pharma for natural killer (NK) cell therapeutics in oncology. Innate is also eligible to receive a total of up to $1.43bn (€1.35bn) in preclinical, clinical, regulatory and commercial milestone payments and royalty payments on net sales in the future.

Pharma 105

Pharma Engineering Marketing Manufacturing 105

Pharmaceutical Technology

APRIL 10, 2023

Aviceda’s HALOS (high-affinity ligands of sigelcs) nanotechnology platform leverages glycobiology to modulate the innate immune system to develop advanced breakthrough therapeutics, focusing on immuno-oncology. Aviceda Glycotech has been created as an oncology-focused spin-off company from Aviceda Therapeutics and Queen’s.

Medicine 103

Medicine Medical 103

Pharmaceutical Technology

SEPTEMBER 8, 2022

On concluding the deal, the Good Therapeutics team intends to leverage its technology to design conditionally active therapies for other immuno-oncology targets and further in a new firm, Bonum Therapeutics.

Biopharma 111

Biopharma Manufacturing Patients Pharma 111

Pharmaceutical Technology

OCTOBER 14, 2022

It is currently being assessed in combination with Merck’s anti-PD-1 therapy, Keytruda, as an adjuvant treatment for high-risk melanoma patients in a Phase II clinical trial being conducted by Moderna.

Pharmaceutical 115

Pharmaceutical Management Patients Medical 115

Pharmaceutical Technology

JUNE 19, 2023

Coherus BioSciences has signed a definitive merger agreement to buy clinical-stage immuno-oncology (I-O) company Surface Oncology, in a deal valued at $65m. Coherus BioSciences will gain access to Surface Oncology’s two differentiated clinical stage assets, SRF388 and SFR114.

Food and Drug Administration 52

Food and Drug Administration Food Competition FDA 52

pharmaphorum

OCTOBER 17, 2022

Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed. Marie-Louise Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development.

Recruitment 97

Recruitment Patients Leads Medicine 97

pharmaphorum

OCTOBER 26, 2022

The stream of novel targets will leverage the proprietary discovery platforms of Normunity’s scientific founder Dr Lieping Chen, an immuno-oncologist who was one among other contributors within the field to identify PD-L1 (B7-H1). The emerging targets will be interrogated and validated together pre-clinically and clinically.

Medicine 52

Medicine Leads Medical Patients 52

European Pharmaceutical Review

MAY 4, 2023

Martin Vogel, Janssen’s Therapeutic Area Lead Oncology for the Europe, Middle-East and Africa (EMEA) region shared with EPR what makes the BsMAb promising for treating this indication. Clinical Lung Cancer. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. 2022; 24(2): 89 – 97.

Food and Drug Administration 94

Food and Drug Administration Safety Medicine Patients 94

European Pharmaceutical Review

FEBRUARY 7, 2023

MSD (Merck & Co) and Nectin Therapeutics have agreed to enter into a clinical trial collaboration, to investigate anti-PVR monoclonal antibody NTX1088 in combination with KEYTRUDA ® (pembrolizumab). The Phase I , open label clinical trial was initiated in November 2022.

Safety 52

Safety Patients Leads Pharmaceutical 52

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Oncolytic viral proteins. Rubius Therapeutics and Pathovax are in second and third positions, respectively.

Leads 52

Leads Pharmaceutical Pharma 52

European Pharmaceutical Review

FEBRUARY 15, 2023

The results suggest “that neoadjuvant nivolumab was safe in long-term follow-up,” commented Patrick Forde, MBBCh, an Associate Professor of oncology and Director of the Thoracic Oncology Clinical Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Food and Drug Administration 91

Food and Drug Administration Patients Food Networking 91

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Microbio t a restoration therapy. By means of geographic reach, the Spanish National Research Council holds the top position.

Leads 98

Leads Pharmaceutical Manufacturing Healthcare 98

Pharmaceutical Technology

APRIL 14, 2023

This will speed up the discovery stage and accelerate the timeline for the clinic. Twist CAR and TCR Libraries allow researchers and drug developers to fine-tune these receptors to address the challenges of cell therapies, including off-target toxicity, enabling rapid advancement toward the clinic.”

Leads 98

Leads Pharmaceutical Patients 98

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Bispecifics head and Immuno-oncology senior vice-president John Lin said: “At Regeneron, we're focused on developing a paradigm-changing portfolio of oncology medicines for patients by combining a deep understanding of cancer biology with cutting-edge technologies.

Pharmaceutical 52

Pharmaceutical Medicine Sales Leads 52

Pharmaceutical Technology

JUNE 6, 2023

According to Globaldata, it is involved in 1 clinical trial, which is ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Buy the model here. MRNA-0184 Overview mRNA-0184 is under development for the treatment decompensated heart failure.

Sales 40

Sales Leads Patients 40

Pharmaceutical Technology

MAY 24, 2023

CohBar has entered into a definitive merger deal with Morphogenesis to advance a late-stage clinical immuno-oncology pipeline of therapies to overcome resistance to cancer immunotherapy.

Leads 52

Leads Patients Management Pharmaceutical 52

Pharmaceutical Technology

JUNE 12, 2023

Astellas Pharma executive director and immuno-oncology development interim head Pranob Bhattacharya stated: “Gastric cancer remains the third deadliest cancer in Japan, leading to approximately 50,000 deaths per year despite significant strides to reduce the impact of this cancer. Zolbetuximab is an investigational Claudin 18.2

Pharma 52

Pharma Patients Leads 52

pharmaphorum

AUGUST 1, 2022

It’s the second oncology-focused deal for Ipsen in the space of a few weeks, coming after its agreed a $250 million acquisition of US pharma Epizyme and its first-in-class EZH2a inhibitor Tazverik (tazemetostat) for follicular lymphoma and epithelioid sarcoma. chains on TCRs, which then activate them to attack tumours.

Pharma 52

Pharma Prescription Leads Marketing 52

Pharmaceutical Technology

JANUARY 4, 2023

Under the multi-year partnership, Belharra and Genentech will employ the former’s platform for developing medicines in therapeutic areas including immuno-oncology, oncology, neurodegenerative and autoimmune diseases. These compounds will be co-developed through Phase I.

Medicine 52

Medicine Sales Leads Pharmaceutical 52

European Pharmaceutical Review

MARCH 20, 2023

. “The data presented by OncoC4 on their ONC-392 monoclonal antibody indicate a differentiated safety profile and encouraging clinical activity in various types of tumors.

Safety 88

Safety Medical Pharmaceutical Marketing 88

Pharmaceutical Technology

OCTOBER 7, 2022

“We believe that compelling genetic and experimental evidence of the role for Fzd4-specific Wnt signalling in retinal vascular function points to the potential clinical impact of our approach.”. The post Surrozen and Boehringer partner to develop therapy for retinal diseases appeared first on Pharmaceutical Technology.

Sales 59

Sales Pharmaceutical 59

Contrarian Sales Techniques

DECEMBER 14, 2022

This year, the sector suffered from various clinical setbacks. This performance helped the company recover from the decline in its oncology business, especially in the US, where the emergence of biosimilars has affected the sales of multiple blockbusters such as Herceptin and Rituxan. Anderson joined Genentech in 2006.

Sales 52

Sales Pharmaceutical Marketing Patients 52

European Pharmaceutical Review

JUNE 27, 2023

In April 2023, MaaT Pharma announced that the FDA cleared the Investigational New Drug (IND) application to initiate in the US Phase III pivotal clinical trial evaluating MaaT013 for the treatment of acute graft vs host disease. What are the most promising microbiome therapeutics in clinical development?

Food and Drug Administration 101

Food and Drug Administration Manufacturing Medicine Pharma 101

Pharmaceutical Technology

JUNE 4, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: T-cell culturing. Whilst Seattle Children's Hospital and Qurgen stand in second and third positions, respectively.

Leads 52

Leads Pharmaceutical Media Medical 52

Pharmaceutical Technology

MARCH 14, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Photodynamic cancer therapy drugs. Massachusetts General Hospital and Calidi Biotherapeutics are in second and third positions, respectively.

Leads 72

Leads Biopharma Pharmaceutical Manufacturing 72

Pharmaceutical Technology

JANUARY 2, 2023

Lifirafenib maleate is under clinical development by BeiGene and currently in the Phase II in clinical pathway. It is specialized in the development and commercialization of immuno-oncology medicines to treat cancers. It targets both epidermal growth factor receptor (EGFR) and B-RAF kinase.

Specialization 40

Specialization Pharmaceutical Medicine Patients 40

Clarivate

JUNE 23, 2022

As part of our Drugs to Watch series, our team of oncology experts pored over thousands of abstracts for presentations at this year’s just-concluded American Society of Clinical Oncology (ASCO) Annual Meeting. To learn more, check out our report, Oncology Drugs to Watch: Top 15 takeaways from ASCO 2022. About the author.

Food and Drug Administration 52

Food and Drug Administration Marketing Doctors Patients 52

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company operates manufacturing plants in Frosinone, Italy; Camacari Brazil; and Malta.

Manufacturing 40

Manufacturing Pharmaceutical Medicine Marketing 40

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Manufacturing 40

Manufacturing Pharmaceutical Medicine Marketing 40

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company operates manufacturing plants in Frosinone, Italy; Camacari Brazil; and Malta.

Manufacturing 40

Manufacturing Pharmaceutical Medicine Marketing 40

pharmaphorum

SEPTEMBER 7, 2022

The deal is due to close in the third quarter of this year, and according to Roche’s head of pharma partnering James Sabry “nicely complements our efforts on next-generation PD-1-targeted IL-2 therapeutics and our broader oncology strategy.” Good’s lead drug is due to start clinical testing next year.

Side effects 52

Side effects Biopharma Engineering Pharma 52

Pharmaceutical Technology

MARCH 14, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Platinum-based cancer drug compositions. BioMarin Pharmaceutical and Eisai are in second and third positions, respectively.

Leads 52

Leads Pharmaceutical Pharma 52

Pharmaceutical Technology

FEBRUARY 19, 2023

Zelenoleucel is under clinical development by Marker Therapeutics and currently in Phase II for Refractory Acute Myeloid Leukemia. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered as an intravenous infusion.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

FEBRUARY 16, 2023

This is said to be essential to determine in the clinic the complete spectrum of treatment effects, including immuno-oncology. It enables quick evaluation of a patient tumour response to a range of cancer drug modalities within 14 days of obtaining harvested samples of tumour cells.

Pharmaceutical 96

Pharmaceutical Patients Medicine Leads 96

Pharmaceutical Technology

FEBRUARY 19, 2023

LYT-200 is under clinical development by Puretech Health and currently in Phase II for Metastatic Pancreatic Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharmaceutical 40

Pharmaceutical 40